Table 1 Study and patient characteristics
Number of studies (n = 92) | % of studies | ||
|---|---|---|---|
Study characteristics | |||
Year of publication | 2000–2006 | 8 | 8.7% |
2007–2011 | 31 | 33.7% | |
2012–2017 | 42 | 45.7% | |
2018–2019 | 11 | 11.9% | |
Geographic region | Europe | 33 | 35.9% |
North America | 29 | 31.5% | |
Asia | 19 | 20.7% | |
Multi | 8 | 8.7% | |
Australia/New Zealand | 3 | 3.3% | |
Study design | Parallel RCT | 91 | 98.9% |
Cluster RCT | 1 | 1.1% | |
Setting | Multi-centre | 55 | 59.8% |
Single-centre | 36 | 39.1% | |
Sample Size | < 50 | 25 | 30% |
50–149 | 31 | 33% | |
150–249 | 9 | 11% | |
250–499 | 13 | 9% | |
500–999 | 8 | 4% | |
≥ 1000 | 14 | 15.5% | |
Study duration (months)a | < 12 | 18 | 19.6% |
12 | 58 | 63.0% | |
13–23 | 4 | 4.3% | |
24 | 10 | 10.9% | |
36 | 2 | 2.2% | |
Frequency of interventions examined | Aflibercept | 5 | 6% |
Bevacizumab | 27 | 34% | |
Bevacizumab+IVTA+PDT | 1 | 1% | |
Bevacizumab+PDT | 5 | 6% | |
Brolucizumab | 2 | 2% | |
Conbercept | 1 | 1% | |
DXM | 1 | 1% | |
DXM+PDT+ranibizumab | 1 | 1% | |
DXM+ranibizumab | 3 | 4% | |
IVTA | 4 | 5% | |
IVTA+Bevacizumab | 2 | 3% | |
IVTA+PDT | 7 | 9% | |
IVTA+ranibizumab | 1 | 1% | |
PDT | 15 | 19% | |
PDT+ranibizumab | 10 | 13% | |
Placebo | 8 | 10% | |
Ranibizumab | 42 | 53% | |
Number of studies by outcome | Vision gain | 48 | 61% |
Vision loss | 51 | 65% | |
Mean BCVA | 77 | 97% | |
Legal blindness | 8 | 10% | |
Vision-related function | 6 | 8% | |
All-cause mortality | 45 | 57% | |
Arterial thromboembolic events | 18 | 23% | |
Venous thromboembolic events | 11 | 14% | |
Bacterial endophthalmitis | 24 | 30% | |
Retinal detachment | 20 | 25% | |
AE | 22 | 28% | |
Serious AE | 23 | 29% | |
Withdrawals due to AE | 16 | 20% | |
Patient characteristics | |||
Total # patients: 24,717 Mean number of patients (range): 655.77 (7–4300) Mean age in years (range): 75.3 (60.0–83.0)a % Female (range): 0.0–74.0% | |||
Mean age (years)b | 60-70 | 3 | 4% |
70-75 | 7 | 9% | |
75-80 | 21 | 27% | |
> 80 | 1 | 1% | |
NR | 45 | 57% | |
% female | < 47.0% | 14 | 18% |
48.0–57.0% | 13 | 17% | |
58.0–62.0% | 19 | 24% | |
62.5–65.0% | 11 | 14% | |
66.0–74.0% | 13 | 16% | |
NR | 9 | 11% | |
% patients with hypertension | 0.0–50.0% | 4 | 5% |
51.0–78.0% | 3 | 4% | |
NR | 72 | 91% | |
Lens status | Mixed | 6 | 8% |
Pseudophakic | 4 | 5% | |
Phakic | 1 | 1% | |
NR | 79 | 87% | |